Application No.: 10/777,524 Docket No.: 140942001311

AMENDMENTS TO THE CLAIMS

- 1-20. (canceled)
- 21. (currently amended) A substantially pure or isolated polypeptide comprising [an] the amino acid sequence of SEQ ID NO: 2 or 4, or a fragment thereof.
 - 22. (canceled)
- 23. (previously presented) A composition comprising the polypeptide of Claim 21 and a suitable carrier.
- 24. (previously presented) The composition of Claim 23, wherein the carrier is an aqueous compound.
- 25. (previously presented) The composition of Claim 24, wherein the aqueous compound selected from the group consisting of: water, saline, and a buffer solution.
- 26. (previously presented) The polypeptide of Claim 21, wherein the polypeptide is fused to a detection or purification tag.
- 27. (previously presented) The polypeptide of Claim 26, wherein the detection or purification tag is selected from the group consisting of: FLAG. His6, or Ig sequence.
 - 28. (previously presented) A kit comprising the polypeptide of Claim 21 and:
 - a) a compartment comprising the polypeptide; and
 - b) instructions for use or disposal of the kit.
- 29. (previously presented) The polypeptide of Claim 21, wherein the polypeptide is recombinantly produced.

Application No.: 10/777,524 Docket No.: 140942001311

30. (withdrawn) A method of modulating physiology of a cell comprising contacting the cell with the polypeptide of Claim 21.

- 31. (withdrawn) The method of Claim 30, wherein the cell is a myeloid cell.
- 32. (withdrawn) The method of Claim 31, wherein the myeloid cell is a monocyte or dendritic cell.